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Background and Purpose—Uric acid (UA) increases the neuroprotective effects of recombinant tissue plasminogen
activator (rt-PA) in experimental ischemia. In patients with stroke, increased UA levels have been linked to better stroke
recovery, but the clinical safety of dual administration of UA and rt-PA is unknown.
Methods—Using a double-blind design, we assessed the safety of exogenous UA in patients with acute stroke treated with
rt-PA. Patients were randomized to an intravenous solution of 500 mL of 5% mannitol/0.1% lithium carbonate (vehicle
group, n8) or 500 or 1000 mg of UA (n16). Safety end points at day 90, lipid peroxidation (serum malondialdehyde),
and serum kinetics of UA were established.
Results—Twenty-four patients with stroke were treated with rt-PA within mean (SD) 133 (35) minutes of clinical onset
(admission National Institutes of Health Stroke Scale score mean [SD] 11 [7], age 71 [10.6] years, 71% males). Levels
of UA decreased in the vehicle group and increased for approximately 24 hours in the high dose of UA group, which
also had lower levels of malondialdehyde at day 5. Mortality (12.5%), symptomatic central nervous system bleeding
(0%), and outcome at day 90 were similar in the 3 treatment arms; one patient in the high-dose group had a mild gouty
episode.
Conclusions—The administration of UA appears to be safe, decreases lipid peroxidation, and prevents an early fall of UA
in serum in patients treated with rt-PA within 3 hours of stroke onset. The clinical efficacy of dual administration of
exogenous UA and rt-PA deserves further investigation in a larger acute stroke trial. (Stroke. 2007;38:2173-2175.)
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Recombinant tissue plasminogen activator (rt-PA) is theonly approved therapy for selected patients with acute
ischemic stroke, but the fear of bleeding complications make
few eligible patients benefit from this therapy.1 Oxidative
damage has been related to reperfusion injury in preclinical
studies,2 but the role of dual therapy with antioxidants and
thrombolytic agents have provided conflicting results in
clinical trials.3,4
Uric acid (UA) is a potent natural antioxidant in man,5 and
its administration has been advocated for patients with acute
stroke.6 Increased levels of serum uric acid were associated
with poorer stroke outcome in a recent study,7 but higher
levels of UA at stroke admission predicted better outcome in
studies that controlled for the effects of confounding factors.8
In experimental ischemia, administration of UA with or
without rt-PA reduced the volume of brain infarction and
improved neurological function,9,10 and in healthy volunteers,
it was safe, increased antioxidant capacity, and decreased
oxidative stress.11,12 This study assessed the safety of dual
treatment with UA and rt-PA in acute stroke.
Methods
The study is a single center, double-blind, randomized, vehicle-
controlled trial of intravenous administration of UA in 24 consecu-
tive patients with acute stroke treated with rt-PA (0.9 mg/kg) within
3 hours of onset. The study was approved by an Institutional Review
Board and the Spanish Drug Agency (eudraCT 2004 to 002937-37),
and all participants or legal representatives gave written informed
consent. Main exclusion criteria were history of gout, renal disease,
or intake of drugs that may increase UA levels. The neurological
examination was assessed using the National Institutes of Health
Stroke Scale (NIHSS) by neurologists certified on its use, and stroke
worsening required at least a 4-point change in the NIHSS score.
Patients received rt-PA and were randomized using a computer-
generated number sheet to receive 500 mg of UA (n8), 1 g of UA
(n8), or vehicle alone (n8) at the end of rt-PA infusion. Vehicle
consisted of a 500-mL solution of 5% mannitol and 0.1% lithium
carbonate to assure the iso-osmolarity and solubility of the prepara-
tion. Trial drug was administered intravenously over 90 minutes and
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it was prepared according to Good Manufacturing and Clinical
Practices. The primary safety end point was the rate of gout attack.
The premature termination of the study was anticipated if 2 patients
experienced a severe gout attack that required aggressive antiinflam-
matory therapy.
The kinetics of UA wee assessed using a Dax analyzer (Bayer-
Technichon, Terrytown, N.J.) with an interassay coefficient of
variation lower than 3.5%. Data were analyzed by noncompartmental
techniques and the elimination rate constant (Ke) was determined
from the slope of the terminal elimination phase of the curve of UA
concentrations against time. The investigators were blind to the
levels of UA until the end of the study. Lithium concentration was
analyzed at the end of the infusion and plasma malondialdehyde, a
marker of lipid peroxidation, was measured by high-performance
liquid chromatography at baseline and at days 2 and 5.
Statistics
Paired Student t test and 2 test were used as appropriate, and serial
changes in serum levels of UA and NIHSS score were assessed using
repeated-measures analysis of variance with Scheffe correction.
Significance was at the P0.05 level.
Results
Patients Characteristics
There were no significant differences in baseline character-
istics among the 3 treatment groups (Table 1). rt-PA was
initiated within mean (SD) 133 (35) minutes of stroke onset,
and UA/vehicle was initiated within 212 (42) minutes.
Safety and Clinical Outcome
One patient (admission UA, 11.0 mg/dL; peak UA, 16.1
mg/dL) experienced mild acute arthritis within 24 hours after
the infusion of 1 g of UA that rapidly resolved with
antiinflammatory drugs. Mortality (12.5%) and symptomatic
intracerebral hemorrhage (0%) did not differ among the 3
treatment arms (Table 2). Deaths were attributed to recurrent
stroke, in one patient allocated vehicle and malignant infarc-
tion and cancer in 2 patients allocated 1 g of UA. Serial
changes in NIHSS score and rate of favorable outcome at day
90 did not differ among the 3 treatment groups as shown in
Table 2.
Pharmacokinetics of Uric Acid
Uric acid showed a maximal decrease 6 to 7 hours after the
onset of stroke in patients allocated vehicle as shown in the
Figure. Contrarily, patients treated with 500 mg of UA did
not show this decrement of UA levels, and those treated with
1 g showed an increment of UA that remained above baseline
levels for approximately 24 hours (elimination half-life of 44








Age years, mean (SD) 70.2 (13) 70.2 (8) 72.9 (12)
Minutes to rt-PA, mean (SD) 128 (29) 139 (42) 131 (37)
Minutes to UA or vehicle, mean (SD) 206 (23) 223 (60) 207 (38)
Male gender, n 8 5 4
High blood pressure, n 6 5 5
Diabetes, n 3 1 2
Hypercholesterolemia, n 2 3 3
Baseline parameters, mean (SD)
NIHSS score 8.5 (4.8) 9.5 (6.4) 14.2 (8.9)
Systolic blood pressure, mm Hg 142.5 (33) 153.5 (15) 151.5 (21)
Creatinine, mg/dL 1.2 (0.2) 1.0 (0.1) 1.0 (0.2)
UA, mg/dL 6.8 (2.3) 6.0 (1.7) 5.7 (0.9)
Malondialdehyde, nmol/L 52.7 (19.3) 55.3 (18.9) 79.1 (54.4)
Malondialdehyde change at day 5, % 27.5 23.4 32.5









Vascular death, n (%) 1 (13) 0 1 (13) 0.58
Symptomatic central nervous system bleeding, n (%) 0 0 0   
Improvement at day 7, n (%) 4 (50) 6 (75) 4 (50) 0.50
NIHSS score at day 90, mean (SD) 2 (2.8) 1.3 (1.5) 5.2 (7.1) 0.24
Modified Rankin scale 0 to 1 at 3 months, n (%) 1 (13) 4 (50) 3 (38) 0.26
Acute arthritis, n (%) 0 0 1 (13) 0.35
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hours). Lithium concentration measured at the end of the
infusion resulted in values of 0.52 (0.12) mEq/L (normal
range values of the laboratory, 0.30 to 1.00 mEq/L).
Malondialdehyde
At day 5, patients allocated the high-dose of UA showed a
decrement of malondialdehyde levels, whereas patients allo-
cated the low dose or vehicle showed an increment (32.5%,
23.4%, and 27.5%, respectively; P0.003).
Discussion
In this pilot study, we did not find any serious adverse events
related to the administration of UA in patients receiving
rt-PA. Only one patient experienced a mild and transient
arthritic bout that completely resolved with antiinflammatory
therapy. The rates of death (12.5%) or intracerebral hemor-
rhage (0%) were not higher than in open-label studies of
rt-PA use in acute stroke.13
A very early assessment of the levels of UA allowed the
identification of a rapid reduction of UA after stroke only in
untreated patients, which was maximal 6 hours after the onset
of symptoms. The study also showed lower lipid peroxidation
at follow up in patients allocated the high-dose of UA. These
findings accord with acute stroke studies describing a pro-
gressive decline of intracellular and extracellular antioxidants
such as superoxide dismutase, carotenoids, or vitamin E.14 A
fall of antioxidant vitamins in plasma has also been associ-
ated with increased oxidative stress and worse stroke out-
come.15 All participants received a vehicle that contained
mannitol and lithium, but we disregard any significant con-
tribution of these agents to the clinical results given the very
low doses that were administered. The study was not powered
to evaluate whether dual therapy with UA and rt-PA im-
proved the clinical outcome at follow up.10 Yet, the early
consumption of UA observed in untreated patients, the effect
on lipid peroxidation, and the lack of serious adverse effects
support additional clinical assessment of UA administration
in acute stroke. The low cost of UA is an additional bonus for
a larger trial because even a mild clinical benefit would be
cost-effective.
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